传染科

订阅

MedSci主页 / 所有栏目 / 传染科

邀请函：2022中国抗病毒药物研发大会即将起航！

2022-06-29 网络 网络

中国抗病毒药物研发大会
关注

自2020年至今，中国抗病毒药物研发大会已连续举办两届，并吸引了行业顶级科学家、企业家、投资家及专家共同参与，目前已发展成为产业探讨抗病毒领域创新及发展的重要平台。

由中国医药生物技术协会、中国医药企业管理协会、苏州市相城区人民政府指导，苏州市相城区黄埭镇人民政府、苏州市相城区望亭镇人民政府主办，苏州市相城区科学技术局、苏州市相城区卫生健康委员会、苏州市相城区市场监督管理局、苏州市相城区生物医药产业发展有限公司、相城生命科技港协办，E药经理人承办的“2022（第三届）中国抗病毒药物研发大会”将于7月10～11日在苏州举行。

 

自2020年至今，中国抗病毒药物研发大会已连续举办两届，并吸引了行业顶级科学家、企业家、投资家及专家共同参与，目前已发展成为产业探讨抗病毒领域创新及发展的重要平台。

 

新冠疫情的暴发与持续，使得当今世界处于百年未有之大变局，为了更好的推动抗病毒领域的科技创新，持续为中国疾病防控做贡献，2022年第三届中国抗病毒药物研发大会将以“百年变局·聚力创新”为主题展开，williamhill asia 将持续与主管政府部门、行业智库、国内外企业家、科学家和投资家们共同展望并研讨在中国可行的抗病毒药物及疫苗最新研发趋势。

 

1、会议时间

2022年7月10—11日

2、会议地点

苏州珀丽春申湖度假酒店一楼玫瑰厅（苏州市相城区黄埭镇春秋路28号）

3、组织机构

指导单位：中国医药生物技术协会、中国医药企业管理协会、苏州市相城区人民政府

主办单位：苏州市相城区黄埭镇人民政府、苏州市相城区望亭镇人民政府

协办单位：苏州市相城区科学技术局、苏州市相城区卫生健康委员会、苏州市相城区市场监督管理局、苏州市相城区生物医药产业发展有限公司、相城生命科技港

承办单位：E药经理人

支持单位：中国生物技术股份有限公司

支持媒体：同写意、药智网、钛媒体、国医国药、williamhill asia 医学

版权声明：
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于williamhill asia 医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章，或“williamhill asia 号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系，williamhill asia 将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1292567, encodeId=be47129256ecd, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Jul 01 05:16:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300529, encodeId=faf913005292c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jul 01 05:16:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301510, encodeId=965113015108a, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Jul 01 05:16:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363373, encodeId=2c6413633e3cb, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Fri Jul 01 05:16:44 CST 2022, time=2022-07-01, status=1, ipAttribution=)]
    2022-07-01 yahu

    #抗病毒#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1292567, encodeId=be47129256ecd, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Jul 01 05:16:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300529, encodeId=faf913005292c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jul 01 05:16:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301510, encodeId=965113015108a, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Jul 01 05:16:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363373, encodeId=2c6413633e3cb, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Fri Jul 01 05:16:44 CST 2022, time=2022-07-01, status=1, ipAttribution=)]
    2022-07-01 lqvr

    #研发#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1292567, encodeId=be47129256ecd, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Jul 01 05:16:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300529, encodeId=faf913005292c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jul 01 05:16:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301510, encodeId=965113015108a, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Jul 01 05:16:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363373, encodeId=2c6413633e3cb, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Fri Jul 01 05:16:44 CST 2022, time=2022-07-01, status=1, ipAttribution=)]
    2022-07-01 huirong

    #药物研发#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1292567, encodeId=be47129256ecd, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Jul 01 05:16:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300529, encodeId=faf913005292c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jul 01 05:16:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301510, encodeId=965113015108a, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Jul 01 05:16:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363373, encodeId=2c6413633e3cb, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Fri Jul 01 05:16:44 CST 2022, time=2022-07-01, status=1, ipAttribution=)]
    2022-07-01 yangshch

    #抗病毒药物#

    0